[{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"9fe0152c-72e1-4a52-bb9d-c984450578a4","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT05700903","created_at":"2023-01-26T15:02:58.180Z","updated_at":"2024-07-02T16:34:26.941Z","phase":"Phase 4","brief_title":"Contributions to Hypertension With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05700903 - ARCH","lead_sponsor":"University of Colorado, Denver","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-06-12"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"782a5ecf-bb65-4e4c-b555-8f76c641cb22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02918968","created_at":"2021-05-21T16:57:57.596Z","updated_at":"2024-07-02T16:36:29.933Z","phase":"Phase 4","brief_title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT02918968","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NKX2-1","pipe":"","alterations":" ","tags":["NKX2-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • flutamide"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 11/02/2016","start_date":" 11/02/2016","primary_txt":" Primary completion: 03/27/2020","primary_completion_date":" 03/27/2020","study_txt":" Completion: 03/27/2020","study_completion_date":" 03/27/2020","last_update_posted":"2021-05-21"},{"id":"fc773c10-831d-4093-bf18-8c93ac9d8441","acronym":"","url":"https://clinicaltrials.gov/study/NCT00699907","created_at":"2021-01-18T02:37:00.384Z","updated_at":"2024-07-02T16:37:08.718Z","phase":"Phase 2a","brief_title":"Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer","source_id_and_acronym":"NCT00699907","lead_sponsor":"University of Arizona","biomarkers":" BRCA1 • BRCA2 • ERBB4 • CSF1R","pipe":" | ","alterations":" BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression","tags":["BRCA1 • BRCA2 • ERBB4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flutamide"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2018-07-24"}]